Trends of Human Embryonic Stem Cell Market (hESC) Products 2017

Published : Oct-2013

The report “Opportunities in Human Embryonic Stem Cell (hESC) Products – Trends and Forecasts to 2017” by BioInformant Worldwide, L.L.C is now available at Contact [email protected] with report name in subject line and your contact details to purchase this report or get your questions answered.

This report is available at a flat 10% Discount on all license types till October 31, 2013. Listed above are original prices and the discount is applicable on the same.

Stem cells are primitive cells found in all multi-cellular organisms that are characterized by self-renewal and the capacity to differentiate into any mature cell type. Categorized by stage of life, several broad categories of stem cells exist, including: Embryonic stem cells, derived from blastocysts; Post-natal stem cells, derived from newborn tissues; Adult stem cells, found in adult tissues – including hematopoietic stem cells, mesenchymal stem cells, neural stem cells, and more; Induced pluripotent stem cells, reprogrammed from adult cells; Cancer stem cells, which give rise to clonal populations of cells that form tumors or disperse in the body.

Complete report available @ .

Embryonic stem cells are stem cells derived from the inner cell mass of a blastocyst, which is a stage reached four to five days post-fertilization. They are the most pluripotent of all stem cell types and can develop into over 200 different cell types of the human body. Human embryonic stem cells (hESCs) were first derived from mouse embryos in 1981 by Martin Evans and Matthew Kaufman, and independently by Gail R. Martin. In 1995, the first successful culturing of embryonic stem cells from non-human primates occurred at the University of Wisconsin-Madison. Another breakthrough followed at the University of Wisconsin-Madison in November 1998 when a group led by Dr. James Thomson developed a technique to isolate and grow hESCs derived from human blastocysts.

As such, embryonic stem cells are still a relatively new discovery, as the first mouse embryonic stem cells (ESCs) were derived from embryos in 1981, but it was not until 1995 that the first successful culturing of embryonic stem cells from non-human primates occurred and not until November 1998 that a technique was developed to isolate and grow embryonic stem cells from human blastocysts.

Inquire for discount @ .

Market Segments

To facilitate research resulting from these advances, a large and diverse market has emerged for human embryonic stem cell products, platforms, and technologies. In total, the global sales of these items compose the hESC product marketplace. One thriving component of this marketplace is the segment of companies that sell hESC research products to scientists.

Termed “research supply companies” or “research product vendors,” large companies selling human embryonic stem cell research products include Life Technologies, BD Biosciences, Thermo Fisher Scientific, EMD Millipore, Sigma Aldrich, Lonza, R&D Systems, and STEMCELL Technologies, as well as more than 60 other suppliers that range in size from multinational corporations to small specialty companies. Together, these research supply companies represent a substantial annual percentage of hESC product sales.

As of 2013, the following product categories accounted for more than 85% of all global hESC research product sales: Embryonic stem cell culture products; Embryonic stem cell lines; Antibodies to embryonic stem cell antigens; Bead-based embryonic stem cell separation systems; Embryonic stem cell protein purification and analysis tools; Tools for DNA and RNA-based characterization of embryonic stem cells; Embryonic stem cell specific growth factors and cytokines; Tools for embryonic stem cell gene regulation; Embryonic stem cell services and mechanisms for in vivo and in vitro stem cell tracking.

In addition, pharmaceutical companies also have intense interest in human embryonic stem cell product development. Because of their plasticity and unlimited capacity for self-renewal, hESCs have been proposed for use in a wide range of pharmaceutical applications, including: Drug target validation and testing; Toxicology testing; Tissue engineering; Cellular therapies; Personalized medicine; And more

For this reason, development of hESC products by the pharmaceutical sector also represents a thriving segment of the global hESC product marketplace. Of particular interest to this community is the potential for use of hESCs to heal tissues that have a naturally limited capacity for renewal, such as the human heart, liver and brain.

Furthermore, within the pharmaceutical sector, development of new drugs is extremely costly and the success rate of bringing new compounds to the market is unpredictable. Therefore, it is crucial that pharmaceutical companies minimize late-stage product failures, such as suboptimal pharmacokinetic properties or unexpected toxicity, that can arise when candidate drugs enter the clinical testing stages.

To achieve this, it would be highly desirable to test candidate drugs using in vitro assays of high human relevance as early as possible. Because hESCs have the potential to differentiate into all of the mature cell types of the human body, they represent an ideal cell type from which to design such drug screening assays.

In summary, the unifying factor within the hESC product marketplace is that all companies involved need to understand market forces, trends, metrics, and financials, in order out-compete the competition and make more profitable decisions. Producing hESC products can involve complicated and confusing decisions, but it doesn’t have to. Claim this report to reveal the current and future needs of the hESC marketplace, so you can focus your marketing efforts on the most profitable products, in the most promising research areas, and within the most lucrative domestic and international markets.

Market Characterization

It is also crucial for companies involved in the hESC product marketplace to understand the funding environment which supports hESC research. Within the United States, the federal government is currently an important, although not dominant, source of funding for stem cell research. The reason is that U.S. states are spending almost as much as the federal government on stem cell research and are actually spending more than the federal government on human embryonic stem cell (hESC) research. Private sources also contribute a huge amount of funding to stem cell research, with analysis of recent large gifts summing to over $1.7 billion.

Worldwide, hESC funding also varies widely, with countries varying from “very permissive” to “very limited” in how each elects to fund hESC product and technology development within the federal, private, and not-for-profit sectors.

While there is conclusive evidence that entering the hESC marketplace is financially worthwhile, there are complicating factors for companies that hope to enter the market. Specifically, human embryonic stem cell research is heavily encumbered by patents held by the University of Wisconsin’s Wisconsin Alumni Research Foundation (WARF), which creates significant challenges for companies seeking to develop new products.

As such, this market research report explores the complex intellectual property (IP) landscape affecting development of human embryonic stem cell products, providing clear guidance for companies entering or already within the market, from collaborating with WARF to less costly alternatives – such as circumventing the claims, conducting research off-shore, and developing embryonic stem cell products for other species.

Methods and Methodology

As a technology company, BioInformant’s standard techniques derive market data from sources that utilize high-quality primary research inputs. The following constitute the basis for our research and analysis:

– Preliminary Research – Examination of studies that need further confirmation by the scientific community, using extensive secondary research.

– Fill-gap Research – Selectively sampled and focused primary research as a fill-gap strategy.

– Historic Analysis – Historic analysis of all end-user industries/markets, requiring technology and market evaluations, growth projections, and market size estimation of end-user markets.

– Historic Supply Chain/Raw Materials Analysis – Comprehensive analysis of data for each primary market segment.

– Data Consolidation – Merging historic end-user market data to yield consolidated primary market data.

– Cross Linking – Primary market data (historic) is compared with resulting end-user consolidated market data and the variance in percentages between data sets is calculated by year.

– Variance Determination – A median figure for each year with a tolerance range equal to twice the variance percentage is determined.

– Projections – End-user markets are projected forward (typically 2013-17) based upon historic growth, technology and market trends, and primary research from the market place.

– Variance Factorization – Consolidation of projected end-user market data to yield derived primary market data. The data is adjusted to the historic variance determinations, as above. The resulting data is further verified by confirmatory primary research.

– Confirmatory Primary Research – Resulting data is presented from companies or individuals participating as research partners. Variations from derived data are adjusted to reflect primary research based consensus.

– Electronically Based End-User Surveys – In addition to the methods described above, electronically based end-user surveys are utilized. Surveys are distributed to a comprehensive panel of academic and industry representatives working within the market segment of interest.

Furthermore, the market intelligence contained in this report was compiled using a broad range of sources, including:

– Grant Funding Databases (NIH database, DoD database, and more)

– Patent Databases (USPTO, WIPO)

– Scientific Publication Databases (PubMed, Highwire Press, Google Scholar)

– Product Launch Announcements (Trade Journals, Company Websites, PR News Feeds)

– Financial Data (SEC Filings, Investor Relations Packets)

– International Surveys (Electronically Distributed End-User Surveys)

– And More

Finally, a rare and valuable feature of this report is an end-user survey of 247 researchers (101 U.S. / 146 International) that identify as having human embryonic stem cell research as their core research focus. These findings reveal hESC researcher needs, technical preferences, key factors influencing buying decisions, and more.

Scientist survey results include: Emerging trends within the hESC research sector; Insights into hESC product selection, purchasing decisions, and preferred providers; Crucial trends and unmet market needs within the hESC marketplace; “Tested Sentences” for selling to hESC scientists; Breakdown of the marketing methods used by industry participants; And much more.

Leverage these insider insights to make effective product development decisions, create targeted marketing messages, and produce higher prospect-to-client conversion rates.

In summary, growth in stem cell research has exploded in the past decade, and so the market to supply hESC products and technologies has grown to meet this huge demand. To profit from this rapidly expanding market, you need to understand your key strengths relative to the competition, intelligently position your products to fill gaps in the market place, and take advantage of crucial hESC trends. Claim this must-read industry report to optimally position yourself to sell hESC products.

Key Findings Include:

– Charts, Trends, and Metrics for the hESC Product Market

– Trends for hESC Grants, Scientific Publications, and Patents

– 5-Year Market Size Projections (2013-2017)

– Profitable Opportunities for hESC Product and Technology Development

– Consumer Behavioral Patterns and Preferred Providers

– Preferred Species for ESC Research

– Crucial Trends and Unmet Market Needs

– Breakdown of the Marketing Methods Used by Industry Participants

– “Tested Sentences” for Selling to hESC Scientists

– End-User Survey of hESC Researchers (101 U.S. / 146 International)

Purchase a copy of this report @ .

Browse more reports on Stem Cell Market @ .

Filed in: Biotechnology, Stem Cell
More Reports
Title Price Buy Now

Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User – Global Forecast to 2027

“The stem cell assays market growth can be attributed to factors such as the rising demand for technologically advanced stem cell analysis instruments, increase in the prevalence of cancer & other diseases and rising number of biopharma and & biotechnology companies working on stem cell based therapies.” The stem cell assays market is projected to reach USD 4.5 Billion by 2027 from USD 1.9 Billion in 2022, at a CAGR of 17.7% during the forecast period. The growth of the market is projected to be driven by collaborations and agreements among market players for stem cell assay products & services, launch of new stem cell analysis systems such as flow cytometers and increase in R&D expenditure by biopharmaceutical and biotechnology companies. The viability/cytotoxici......

Nucleic Acid Isolation & Purification Market by Product (Kit, Reagent, Instrument), Method (Column, Magnetic Beads), Type (Genomic DNA, Plasmid DNA, miRNA), Application (Drug Discovery, Diagnostics), End User (Pharma, Biotech) – Global Forecast to 2027

The nucleic acid isolation and purification market is expected to grow at a CAGR of 7.9% in the forecast period. The global nucleic acid isolation and purification market is projected to reach USD 9.2 billion by 2027 from USD 6.3 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth of this market can majorly be attributed to the increasing R&D activities as well as technological advancements and increasing automation. The emerging economies, improving regulatory and reimbursement scenario, and the growing adoption of molecular diagnostics and personalized medicines are expected to offer a wide range of growth opportunities for players in the market. However, the high cost of automated instruments is expected to hinder the growth of the market. As the world be......

Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027

“Rising number of road accidents and associated traumatic wounds and growing incidence of burn injuries are driving the overall growth of the wound care biologics market” The global wound care biologics market is valued at an estimated USD 1.8 billion in 2022 and is projected to reach USD 2.4 billion by 2027, at a CAGR of 5.4% during the forecast period. Market growth is driven by factors such as the growing incidence of burn injuries and the rising number of road accidents and associated traumatic wounds. However, the high cost of wound care biologic products and the risk associated with skin substitute failure are the major factors hampering the growth of this market. “The biological skin substitutes segment accounted for the highest growth rate in the wound care biologics ma......

Bioanalytical Testing Services Market by Type, Application (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User and Region (North America, Europe, APAC, Latin America, MEA) – Global Forecast to 2027

“The global bioanalytical testing services market is projected to grow at a CAGR of 15.6%” Bioanalytical testing involves analytical methods used for the detailed examination of biological and biotechnology products. Bioanalysis enables the quantitative measurement of drugs and their metabolites, biological molecules in unnatural locations or concentrations, DNA, and large molecules. The global bioanalytical testing services market is projected to reach USD 6.0 billion by 2027 from an estimated USD 2.9 billion in 2022, at a CAGR of 15.6% during the forecast period. “The Cell-based assays segment is expected to account for the largest share of the bioanalytical testing services market” The increasing prevalence of chronic diseases and the rising number of clinical trials ar......

Cell Analysis Market by Product & Service (Reagents & Consumables, Instruments), Technique (Flow Cytometry, High Content Screening), Process (Single-cell Analysis), End User (Pharmaceutical and Biotechnology Companies) – Global Forecast to 2027

“Single-cell analysis segment has gained significant traction in the recent years attributed to the widening applications of this technology in cancer research. This is further supplemented by the robust government initiatives targeted towards single-cell analysis research. The growth of the single-cell analysis segment is expected to drive the overall growth of the cell analysis market.” The global cell analysis market is projected to reach USD 28.6 Billion by 2027 from USD 17.7 Billion in 2022, at a CAGR of 10.1% during the forecast period. Key opportunities for the cell analysis market include, emerging economies, high risk of communicable diseases and pandemic outbreak, and increasing adoption of novel cellular assays in various cancer research applications. On the other hand, h......

3D Cell Culture Market by Type (Hydrogel, ECM, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell, Toxicology, Tissue Engineering), End User (Pharma, Biotech, Research, Cosmetics), Region – Global Forecast to 2027

“Increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine is driving the overall growth of the3D Cell culture market” The global 3D cell culture market is valued at an estimated USD 1.3 billion in 2022 and is projected to reach USD 2.6 billion by 2027, at a CAGR of 15.6% during the forecast period. The growth of this market is mainly driven by factors such as the increasing focus on developing alternative methods to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, a lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the f......

Tangential Flow Filtration Market by Product (System, Membrane Filter), Material (PES, PVDF, PTFE), Technique (Ultrafiltration), Application (Final Product Processing, Raw Material Filtration), End User (Pharma, Biotech), Region – Global Forecast to 2027

“Growth in the tangential flow filtration market can be attributed to factors such as the growing advantages of tangential flow filtration over normal flow filtration, rising R&D spending in pharmaceutical & biotechnology industries and increasing adoption of single-use technologies.” The global tangential flow filtration market is projected to USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 13.2% during the forecast period. The rising advantages of tangential flow filtration over normal flow filtration, increasing adoption of single-use technologies, and growing R&D spending in pharma-biotech companies. On the contrary, the high capital investments for setting up new production facilities are expected to restrain the market growth. “In 2021 the s......

Human Microbiome Market by Product (Prebiotics, Probiotics, Food, Diagnostic Tests, Drugs), Application (Therapeutic, Diagnostic), Disease (Infectious, Metabolic/Endocrine), Research Technology (Genomics, Proteomics, Metabolomics) – Global Forecast to 2029

“Increased focus on human microbiome therapy development to drive the growth of this market.” The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029. The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development & development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth. However, a lack of expertise and inadequate research on the human microbiome are factors expected to restrain this market's growth. “By product segment, the drugs segment accounted for the largest share of huma......

Exosome Research Market by Product and services (Kits, Reagents, Instrument), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem cell, Dendritic cell-derived), End User – Global Forecast to 2026

“Increasing interest in exosome-based proceduresto Drive the Growth of Market” The exosome research market is valued at an estimated USD 144 million in 2021 and is projected to reach USD 661 million by 2026, at a CAGR of 35.6% during the forecast period, owing to increased funding for life sciences research, the high global prevalence of cancer, and the increasing interest in exosome-based procedures. “By product & service, the kits & reagents segment accounted for the largest share of the exosome research market” Based on product and service, the exosomes market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is further divided into antibodies, isolation, purification, quantitation kits & reagents, and other ki......

Metagenomic Sequencing Market by Product & Services (Reagent, Consumables, Instrument), Workflow (Sample Preparation, Sequencing), Technology (16S rRNA, Shotgun, Whole-genome), Application (Drug Discovery, Diagnostic) – Global Forecast to 2027

“Continuous technological innovations in NGS platforms is the key factors driving growth in the metagenomic sequencing market’’ The metagenomic sequencing market is expected to reach USD 4.3 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 18.4% during the forecast period. Growth in the metagenomic sequencing market is mainly driven by continuous technological innovations in NGS platforms, increasing initiatives and funding from government & private bodies for large-scale sequencing projects, declining costs of genome sequencing, and the significant applications of metagenomics in various fields. “By technology segment, the shotgun metagenomic sequencing segment accounted for the fastest-growing segment of the metagenomic sequencing market” Based on technol......
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy